CA
NZ
UK
AU
IND
US
…
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -23.71M | -30.16M | -6.53M | -19.52M | -13.52M |
| Net income | -23.88M | -30.22M | -6.72M | -19.60M | -13.55M |
| Selling general administrative | 10.06M | 9.71M | 8.57M | 8.33M | 6.11M |
| Selling and marketing expenses | 3.87M | 3.20M | 2.80M | 2.04M | 3.39M |
| Gross profit | 3.25M | 2.63M | 3.58M | 13.16M | 8.77M |
| Reconciled depreciation | 1.86M | 1.48M | 1.24M | 1.27M | 1.24M |
| Ebit | -23.33M | -29.41M | -6.10M | -8.35M | -11.22M |
| Ebitda | -21.47M | -27.93M | -4.80M | -9.33M | -9.98M |
| Depreciation and amortization | 1.86M | 1.48M | 1.30M | -0.99M | 1.24M |
| Operating income | -25.28M | -19.38M | -15.50M | -8.35M | -11.22M |
| Other operating expenses | 42.24M | 39.60M | 34.19M | 34.84M | 34.98M |
| Interest expense | 0.66M | 0.56M | 0.34M | 8.92M | 0.90M |
| Tax provision | 0.17M | 0.06M | 0.13M | 0.08M | 0.03M |
| Interest income | 1.86M | 2.05M | 2.34M | 0.27M | 0.01M |
| Net interest income | 0.82M | -0.04M | 5.89M | -2.26M | -1.08M |
| Income tax expense | 0.17M | 0.06M | 0.18M | 0.08M | 0.03M |
| Total revenue | 16.96M | 20.22M | 18.69M | 26.50M | 23.76M |
| Total operating expenses | 28.53M | 22.02M | 19.08M | 21.51M | 19.99M |
| Cost of revenue | 13.71M | 17.59M | 15.11M | 13.33M | 14.99M |
| Total other income expense net | 1.57M | -10.78M | 8.97M | -11.18M | -2.30M |
| Net income from continuing ops | -23.88M | -30.22M | -12.43M | -19.60M | -13.55M |
| Net income applicable to common shares | - | - | - | -19.60M | -13.55M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 86.25M | 73.50M | 66.46M | 50.02M | 19.74M |
| Intangible assets | 0.03M | 0.10M | 0.17M | 0.23M | 0.30M |
| Other current assets | 0.36M | 0.46M | 0.72M | 9.98M | 2.71M |
| Total liab | 42.62M | 42.34M | 27.19M | 39.10M | 24.33M |
| Total stockholder equity | 43.63M | 31.15M | 31.59M | 10.91M | -4.58M |
| Other current liab | 20.92M | 22.02M | 4.92M | 6.34M | 2.41M |
| Common stock | 0.26M | 0.21M | 0.18M | 0.14M | 0.07M |
| Capital stock | 0.26M | 0.21M | 0.18M | 0.14M | 0.07M |
| Retained earnings | -228.93M | -205.05M | -174.82M | -168.11M | -148.51M |
| Other liab | - | - | - | 26.20M | 12.21M |
| Other assets | - | - | - | 0.36M | 0.47M |
| Cash | 4.80M | 9.15M | 12.03M | 33.90M | 11.05M |
| Total current liabilities | 25.71M | 26.54M | 10.83M | 12.06M | 10.72M |
| Current deferred revenue | 1.18M | 0.01M | 0.02M | 0.06M | 0.54M |
| Net debt | 3.35M | -2.22M | -5.32M | -33.05M | -9.65M |
| Short term debt | 0.62M | 0.42M | 0.36M | - | 3.08M |
| Short long term debt total | 8.15M | 6.93M | 6.71M | 0.85M | 1.39M |
| Other stockholder equity | 272.33M | 236.00M | 206.25M | 178.88M | 143.87M |
| Property plant equipment | - | - | - | 3.58M | 4.03M |
| Total current assets | 59.96M | 52.16M | 49.70M | 45.84M | 14.95M |
| Net tangible assets | - | - | - | 10.68M | -4.88M |
| Short term investments | 48.34M | 34.01M | 29.68M | - | 0.00M |
| Net receivables | 2.37M | 5.85M | 4.42M | 9.53M | 2.71M |
| Inventory | 4.09M | 2.69M | 2.85M | 1.96M | 1.20M |
| Accounts payable | 3.61M | 4.10M | 5.53M | 5.66M | 4.69M |
| Accumulated other comprehensive income | -0.03M | -0.01M | -0.02M | -0.01M | -0.02M |
| Non currrent assets other | 0.47M | 0.44M | 0.18M | 0.36M | 0.47M |
| Non current assets total | 26.29M | 21.33M | 16.76M | 4.18M | 4.79M |
| Capital lease obligations | 8.15M | 6.51M | 6.35M | 0.85M | 1.39M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -14.04M | -8.40M | -36.95M | -0.48M | 4.00M |
| Change to liabilities | - | - | - | 0.41M | 1.72M |
| Total cashflows from investing activities | -19.54M | -8.40M | -34.32M | -0.48M | 3.55M |
| Net borrowings | - | - | - | -0.70M | -0.69M |
| Total cash from financing activities | 29.62M | 19.39M | 22.92M | 35.76M | -1.05M |
| Change to operating activities | - | - | - | 0.65M | -2.75M |
| Net income | -23.88M | -30.22M | -6.72M | -19.60M | -13.55M |
| Change in cash | -4.36M | -2.71M | -22.03M | 22.85M | -6.33M |
| Begin period cash flow | 9.15M | 11.87M | 33.90M | 11.05M | 17.38M |
| End period cash flow | 4.80M | 9.15M | 11.87M | 33.90M | 11.05M |
| Total cash from operating activities | -14.53M | -13.62M | -10.46M | -11.88M | -8.92M |
| Issuance of capital stock | 27.42M | 22.16M | 41.37M | 38.38M | - |
| Depreciation | 1.71M | 1.48M | 1.30M | 1.27M | 1.24M |
| Other cashflows from investing activities | -12.45M | -2.12M | -27.86M | 0.07M | 0.04M |
| Change to inventory | -1.36M | 0.19M | -0.91M | -0.72M | 0.26M |
| Change to account receivables | 4.88M | -1.02M | 4.76M | -7.58M | 0.93M |
| Other cashflows from financing activities | -1.43M | -1.84M | -1.99M | -1.92M | -1.05M |
| Change to netincome | - | - | - | 13.69M | 3.23M |
| Capital expenditures | 5.50M | 6.27M | 6.46M | 0.56M | 0.49M |
| Change in working capital | 4.77M | 1.27M | 2.34M | -7.24M | 0.16M |
| Stock based compensation | 3.11M | 3.14M | 1.94M | 1.95M | 1.67M |
| Other non cash items | -0.24M | 10.71M | -9.33M | 11.74M | 1.69M |
| Free cash flow | -20.04M | -19.90M | -16.93M | -12.44M | -9.40M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MDWD Mediwound Ltd |
-0.56 4.04% |
13.30 | - | 34.97 | 14.66 | 5.03 | 12.85 | -6.32 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
| Name | Title | Year Born |
|---|---|---|
| Prof. Lior Rosenberg M.D. | Co-Founder & Medical Director | 1946 |
| Mr. Boaz Gur-Lavie CPA, M.B.A. | Chief Financial Officer | 1974 |
| Mr. Yaron Meyer Adv. | Exec. VP, Gen. Counsel & Corp. Sec. | 1979 |
| Dr. Ety Klinger | Chief R&D Officer | 1962 |
| Mr. Ofer Gonen B.Sc. | Chief Exec. Officer | 1973 |
| Mr. Tzvi Palash B.Sc., M.Sc. | Chief Operating Officer | 1957 |
| Mr. Stephen T. Wills CPA, CPA, MST | Exec. Director | 1957 |
| Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc. | Chief Medical Officer | NA |
| Ms. Hani Luxenburg | Chief Financial Officer | 1973 |
| Mr. Ofer Gonen B.Sc. | Chief Executive Officer | 1973 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...